# Phase 1 Clinical Trial of FluBHPVE6E7 Immunotherapy for HPV16-Associated Oropharyngeal Cancer

> **NCT06589609** · PHASE1 · RECRUITING · sponsor: **BlueSky Immunotherapies GmbH** · enrollment: 12 (estimated)

## Conditions studied

- Oropharyngeal Squamous Cell Carcinoma (SCC)

## Interventions

- **BIOLOGICAL:** FluBHPVE6E7

## Key facts

- **NCT ID:** NCT06589609
- **Lead sponsor:** BlueSky Immunotherapies GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-23
- **Primary completion:** 2027-11
- **Final completion:** 2029-11
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06589609

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06589609, "Phase 1 Clinical Trial of FluBHPVE6E7 Immunotherapy for HPV16-Associated Oropharyngeal Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06589609. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*